Although peripheral blood PLA2R antibodies correlate with the severity of aMN and can assist in diagnosis without a kidney biopsy, our findings suggest that PLA2R staining in renal tissue is a more direct and reliable marker for assessing disease severity and predicting outcomes in the context of kidney biopsy. This evidence concerns the gene PLA2R1 and adrenomyeloneuropathy.